Published in Managed Care Business Week, November 9th, 2004
Pursuant to the merger agreement announced on September 28, 2004, Exelixis acquired all of the outstanding shares of capital stock of X-Ceptor in exchange for approximately 2.5 million shares of Exelixis common stock and approximately $2.9 million in cash.
X-Ceptor's development programs will be integrated into Exelixis' discovery group led by Michael Morrissey, PhD. Richard Heyman, PhD, X-Ceptor's former chief scientific officer, will report...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Managed Care Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.